 |
HONG KONG, Nov. 9, 2026 /PRNewswire/ — CSOP Asset Management Limited (“CSOP”), Hong Kong’s largest Exchange Traded Product (“ETP”) issuer[1], announces that the CSOP KIOXIA Daily Max (1.25x) Leveraged Product (7772.HK) will list tomorrow (10 November 2026) on the Hong Kong Stock Exchange (“HKEX”).
CSOP KIOXIA Daily Max (1.25x) Leveraged Product to Debut on HKEX
As the world’s first leveraged product providing daily amplified exposure to KIOXIA Holdings Corporation (“Kioxia“), Japan’s leading memory chip manufacturer, 7772.HK is designed for investors seeking short-term tactical trading opportunities of the memory giant. The launch further expands CSOP’s suite of flagship ETPs aimed at capturing opportunities arising from the AI investment theme, providing investors with differentiated access to key players across Asia’s AI value chain.
With accelerating AI investment globally, memory chips have emerged as a critical component underpinning the next phase of AI infrastructure development. Kioxia is one of the world’s largest manufacturers of memory products, specialising in flash memory and solid-state drives (SSDs)[2]. Leveraging its long-standing market leadership in NAND flash memory, which is widely deployed across cloud computing platforms and data centers, Kioxia has become a key beneficiary of surging AI-driven demand. Since listing on the Tokyo Stock Exchange in December 2024, Kioxia has attracted significant investor interest, becoming one of Japan’s best-performing semiconductor stocks in 2025 amid growing enthusiasm for the sector[3].
According to a recent S&P Global Ratings report[4], Kioxia is expected to maintain exceptionally strong earnings over the next two years, supported by a positive long-term industry outlook. The report also noted the potential for reduced earnings volatility at Kioxia going forward, thanks to the expanding AI market. In addition, Kioxia is reportedly considering a potential American depositary receipt (ADR) listing, reflecting firm confidence in its strategic positioning and growth prospects. Kioxia reported revenue of 2.48 trillion yen for the second quarter of fiscal 2026, up 40.3% quarter-on-quarter and 453.2% year-on-year, with a single quarter’s revenue exceeding the full fiscal 2025 total[5].
The CSOP KIOXIA Daily Max (1.25x) Leveraged Product (7772.HK) aims to provide investment results that, before fees and expenses, closely correspond to the daily targeted leveraged performance of the common stock of Kioxia Holdings Corporation. The product adopts a swap-based synthetic replication strategy and has a listing price of approximately HKD 7.8 per unit, a board lot size of 100 units, and a management fee of 1.6%.
“The launch of the CSOP KIOXIA Daily Max (1.25x) Leveraged Product reflects our ongoing commitment to bringing innovative and differentiated investment tools to the Hong Kong market. The product provides investors with amplified exposure to Kioxia, a memory maker at the forefront of the rapidly evolving semiconductor industry,” said Ms. Ding Chen, CEO of CSOP. “As Asia’s leading issuer of leveraged and inverse products, CSOP will continue to deliver investment solutions that broaden market access and cater to investors with diverse risk appetites.”
Compared with investing in a full board lot of Kioxia shares listed in Japan, 7772.HK offers a more accessible alternative by lowering the investment threshold while providing targeted exposure to Kioxia’s share price performance. As both the product and its underlying stock are traded during Asian market hours, investors can respond promptly to market developments affecting Kioxia and the broader semiconductor sector.
Leveraged and inverse products are designed as short-term trading tools to achieve the stated performance goals during a single-day trading session. Single-stock leveraged products are not intended for holding longer than one day as their return may deviate from the corresponding leveraged performance of the underlying stock over a longer period.
|
[1] HKEX, Bloomberg, CSOP, as of 30th October 2026. Based on assets under management of all share classes of ETFs (including leveraged and inverse products) listed in Hong Kong, excluding ETFs with multiple listings. |
|
[2] Kioxia, FY2025 Financial Results |
|
[3] The Tokyo Stock Exchange |
|
[4] https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3642120 |
|
[5] Kioxia, FY2026 Q2 Financial Results |
About CSOP
CSOP Asset Management is the largest ETF/ETP issuer in Hong Kong*. As of 30th October 2026, CSOP’s total AUM stood at about US$31.1 billion (about HK$245 billion). Supported by a robust ETF ecosystem, CSOP offers a lineup of 73 ETF/ETPs and 5 mutual funds across Hong Kong and Singapore**. In 2026, 7 of the 10 most actively traded ETPs in Hong Kong were managed by CSOP***.
|
*Source: HKEX, Bloomberg, CSOP, as of 30th October 2026. Based on assets under management of all share classes of ETFs (including leveraged and inverse products) listed in Hong Kong, excluding ETFs with multiple listings. |
|
** Source: HKEX, Bloomberg, CSOP, as of 30th October 2026. |
|
***Source: Bloomberg, from 1st January 2026 to 30th October 2026. |
Disclaimer and Important Notices
Investment involves risks. Investors should refer to the Prospectus and the Product Key Facts Statement for further details, including product features and the full list of risk factors. This material is prepared by CSOP Asset Management Limited and has not been reviewed by the Securities and Futures Commission in Hong Kong. Please read the detailed disclosure and disclaimer carefully by accessing website (https://www.csopasset.com/en/education/disclaimer_en_forKioxia125l.html).
